T Lymphocyte Sub-population and cAMP/cGMP Regulating Effect by Processed Ershen Pill Formula

PAN Xin; HU Chang-jiang; GENG Yuan-yuan; ZHAO Ling; XIONG Rui; CHEN Zhi-min

doi:10.13422/j.cnki.syfjx.2014130138

您当前的位置：

首页 >

文章列表页 >

T Lymphocyte Sub-population and cAMP/cGMP Regulating Effect by Processed Ershen Pill Formula

更新时间：2024-01-04

- T Lymphocyte Sub-population and cAMP/cGMP Regulating Effect by Processed Ershen Pill Formula
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 13, Pages: 138-141(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014130138
  CLC： R285.5
- Published：2014
- 稿件说明：
移动端阅览
PAN Xin, HU Chang-jiang, GENG Yuan-yuan, et al. T Lymphocyte Sub-population and cAMP/cGMP Regulating Effect by Processed Ershen Pill Formula[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(13): 138-141.
DOI：

PAN Xin, HU Chang-jiang, GENG Yuan-yuan, et al. T Lymphocyte Sub-population and cAMP/cGMP Regulating Effect by Processed Ershen Pill Formula[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(13): 138-141. DOI： 10.13422/j.cnki.syfjx.2014130138.

摘要

目的：比较二神丸方剂中的两味中药炮制前、后对脾肾阳虚泄泻模型大鼠全血T淋巴细胞亚群和环磷酸腺苷（cAMP）与环磷酸鸟苷（cGMP）比值（cAMP/cGMP）失衡的调节作用，为阐明二神丸中药物炮制增效机制提供实验依据。方法：将50只SD雄性大鼠随机分为正常、模型、阳性对照参芩白术丸2 g·kg-1组，二神丸生品（生补骨脂+生肉豆蔻）3.5 g·kg-1组、二神丸炮制品（盐补骨脂+煨肉豆蔻）3.5 g·kg-1组共5组，通过复合因素造脾肾阳虚泄泻模型4周，并按组给药2周，分别从股动脉和眼眶后静脉丛取全血和血清，用流式细胞仪检测全血各组样本T淋巴细胞亚群CD3+，CD3+CD4+，CD3+CD8+的百分比；用酶联免疫吸附法（ELISA）测定血清样本中环磷酸腺苷（cAMP）和环磷酸鸟苷（cGMP）的水平。结果： 3个给药组均能显著提高模型动物血清中cAMP/cGMP和全血CD3+，CD3+CD4+百分比，而CD3+CD8+百分比则显著降低，且炮制品二神丸组对CD3+，CD3+CD4+，CD3+CD8+百分比和cAMP/cGMP的调节作用明显强于生品二神丸组。结论：复方二神丸中药物经过炮制后能显著恢复脾肾阳虚泄泻模型大鼠全血CD3+CD4+，CD3+CD8+（P<0.01）和血清cAMP/cGMP（P<0.01）的水平，提示二神丸中的两味中药炮制后增强疗效可能与其增强脾肾阳虚泄泻模型大鼠对T细胞网络平衡（CD3+，CD3+CD4+，CD3+CD8+）和cAMP/cGMP平衡的调节作用有关。

Abstract

Objective: To compare the T-lymphocyte sub-population and cyclic adenosine monophosphate(cAMP)/cyclic guanosine monophosphates(cGMP) regulating effect of Ershen pill formula and its processed product on in spleen-kidney YANG deficiency rats

and provide experimental basis for mechanism of Ershen pill processing. Method: Fifty SD male rats were divided into normal group

model group

positive control group

the processed formula Ershen pill group(the crude fructus psoraleae combined with thecrude fructus myristica). The composite factors were used to made the rat spleen-kidney YANG deficiency diarrhea model for 4 weeks

after 2 weeks of admimistration the whole blood and separate serum were collected

flow cytometry and ELISA were used to detect the percentage of CD3+

CD3+CD4+

CD3+ CD8+ and the content of cAMP and cGMP. Result: Compared with the model group

the three dose groups all could significantly improve cAMP/cGMP and the percentage of CD3+

CD3+CD4+

reduce the percentage of CD3+ CD8+

the impact on CD3+

CD3+/CD4+/CD8+ percentage and cAMP/cGMP was more significant in Ershen pill processed group. Conclusion: The components in Ershen pill after processing can recover the lever of CD3+ CD4+

CD3+ CD8+(P<0.01)and cAMP/cGMP (P<0.01)in spleen-kidney YANG deficiency diarrhea rats. This result indicates that the formula Ershen pill after processing can enhance the curative effect

which may be associate with adjusting the balance of T cell network (CD3+ CD4+

CD3+ CD8+)and cAMP/cGMP in spleen-kidney YANG deficiency diarrhea rats.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacologic Action of and Processed Products

Preliminary Study on Soothing Liver and Choleretic Effects of and its Processed Products

Contents Change of Chemical Compositions in Ershen Pills Before and After Preparation

Related Author

XU Nan

CHEN Yi-zhu

ZHAN Hong-li

ZHANG Hong-da

ZHAO Jing-li

GAO Hong-mei

HU Lin

Related Institution

No data

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰